IQVIA Holdings Inc. (IQV)
NYSE: IQVHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IQV stock chart
Technical analysisKey statistics
All statistics- Market cap
- $40.51B
- P/E (TTM)
- 29.91
- Forward P/E
- 17.31
- EPS (TTM)
- $8.22
- Dividend yield
- None
- 52-week range
- 154.50 – 284.50
- Day range
- 245.25 – 252.28
- Volume / Avg
- 1.25M / 1.45M
- Beta
- —
- Shares outstanding
- 164.80M
52-week range
IQV stock today
On Nov 20, IQV ended the session at $245.82, shedding $4.73 (1.89%), versus the S&P 500's 3.70% decline. At this level, IQV sits in the middle of its 52-week range of $154.50 to $284.50: 13.6% below the high, set on Oct 27, 2026 and 59.1% above the low. IQV is up 9.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 9.3%.
At 29.9x trailing earnings, IQVIA trades below the peer-group median of 66.6x. Its forward P/E of 17.3x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About IQVIA
Company profileIQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- CEO
- Mr. Ari Bousbib
- Headquarters
- Durham, NC
- Employees
- 95,000
- IPO year
- 2013
- Website
- iqvia.com
Financial highlights
Full financialsIn fiscal 2025, IQVIA generated $16.31 billion in revenue, up 5.9% from fiscal 2024, its 14th consecutive year of revenue growth. Net income was $1.36 billion (-0.9% year over year), for a net margin of 8.3% versus a median of 7.6% in the prior 5 years. Gross margin was 33.3% (down from 34.9%) and operating margin 13.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $16.31B | $15.40B | $14.98B | $14.41B | $13.87B |
| Growth | +5.87% | +2.81% | +3.98% | +3.86% | +22.14% |
| Net income | $1.36B | $1.37B | $1.36B | $1.09B | $966.00M |
| EPS (diluted) | $7.84 | $7.49 | $7.29 | $5.72 | $4.95 |
Analyst forecast
ForecastConsensus (20 analysts)
none
Avg. price target
$311.89+26.88%
- Strong buy 2
- Buy 16
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 27, 2026
- EPS actual vs est.
- $2.10 vs $2.94
- Surprise
- -28.57%
IQV news
All IQV news- IQVIA Stock Jumps 59% in 6 Months: Here's What You Should KnowNasdaqIQV, ACHC, ALEC
- IQVIA: 3 Key Takeaways for Long-Term InvestorsNasdaq
- Here's Why IQVIA Holdings (IQV) is a Strong Momentum StockNasdaq
- WM Q3 Earnings Miss Estimates, Revenues Increase 6.3% Y/YNasdaqWM, WCN, IQV
- What IQVIA (IQV) Said on Its Q3 Earnings CallNasdaq
- IQVIA (IQV) Q3 2026 Earnings Call TranscriptNasdaq
- IQVIA signals 2026 revenue of $17.350B-$17.500B and adjusted EPS of $12.90-$13.00 as clinical bookings reach $11.7B on an LTM basisSeeking Alpha
- IQVIA Holdings Inc. (IQV) Q3 2026 Earnings Call TranscriptSeeking Alpha
IQVIA peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| INCYIncyte Corp. | 114.63 | -1.07% | $23.36B | vs IQV |
| MEDPMedpace Holdings Inc. | 610.54 | -3.70% | $17.08B | vs IQV |
| CRLCharles River Laboratories International Inc. | 314.32 | -4.15% | $15.06B | vs IQV |
| ICLRICON plc | 186.71 | -1.92% | $13.99B | vs IQV |
| ABSIAbsci Corporation | 7.51 | -7.97% | $1.30B | vs IQV |
| OABIOmniAb Inc. | 4.66 | -7.36% | $679.71M | vs IQV |
| NRCNRC Health | 25.16 | +0.68% | $533.93M | vs IQV |
| MXCTMaxCyte Inc. | 1.37 | +7.03% | $141.45M | vs IQV |
Indexes, lists and sector
Index membership
IQVIA stock FAQ
What is IQVIA's stock price today?
IQV last traded at $245.82 as of Nov 20, 4:00 PM EST, down 1.89% on the day. Prices are delayed at least 15 minutes.
What is IQV's P/E ratio?
IQV trades at a trailing P/E ratio of 29.91 and a forward P/E of 17.31, compared with a median of 66.6 for its closest peers.
Is IQVIA in the S&P 500?
Yes. IQVIA (IQV) is a constituent of the S&P 500 index.
Who is IQVIA's CEO?
Mr. Ari Bousbib is the chief executive officer of IQVIA Holdings Inc., which has about 95,000 employees.
What is the IQV 52-week high?
The 52-week high for IQV is $284.50 and the 52-week low is $154.50. The stock is currently 13.6% below its high.